EuroPCR

PCR is a European organization dedicated to education and information in the field of interventional cardiology and minimally invasive transcatheter procedures. Its activities cover a large spectrum, from the organization of annual courses in Europe, Asia, the Middle East and Africa, to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects. For more information, visit https://www.pcronline.com/Courses/EuroPCR.

Interventional cardiologists in Canada have performed the world’s first implant of a new coronary sinus reducer designed to treat chest pain patients who see no benefits from other available interventional or surgical treatments. The A-Flux Reducer System was designed and developed by VahatiCor, a new medical device company associated with California-based T45 Labs.

Cardiologists detail world’s first implant of new device for ‘no-option’ chest pain patients

The A-Flux Reducer System by VahatiCor was designed to “conform seamlessly” to any patient’s anatomy, and it can be repositioned or retrieved as necessary.

Thumbnail

Reduce, reuse, recycle: How cath labs can lower cardiology’s colossal carbon footprint

Cath labs, like radiology suites and operating rooms, are leading contributors to the world’s growing carbon footprint.

Images coronary calcium imaging by optical coherence tomography (OCT) and high-definition intravascular ultrasound (IVUS).

OCT-guided PCI improves survival after life-threatening heart attacks

Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 

Biolimus A9 Coated Balloon from BioAscend

In-stent restenosis after PCI: New biolimus-coated balloon non-inferior to paclitaxel devices

A new study of nearly 300 PCI patients suggests biolimus-coated balloons could provide significant value to interventional cardiologists in the years ahead.  

The EuroPCR 2024 meeting May 14-17 in Paris included four days of late-breaking interventional cardiology science presentations featured 12,100 participants, more than 550 educational sessions and 12 live cases. Photo courtesy of EuroPCR

5 takeaways from late-breaking studies at EuroPCR

The Society for Cardiovascular Angiography and Interventions offers its top five key takeaways from the EuroPCR 2024 meeting last week.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve noninferior to similar devices from Medtronic, Edwards after 30 days

The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care. 

Cardiologist Heart Doctor Tablet Technology

TAVR, SAVR linked to comparable long-term outcomes, new meta-analysis confirms

Researchers tracked data from more than 7,500 patients, sharing their findings at EuroPCR 2024 in Paris and in JSCAI.

Edwards Lifesciences Sapien 3 Ultra Resilia TAVR

Updated balloon-expandable TAVR valve from Edwards outperforming its predecessors

The fifth-generation valve is associated with improved hemodynamic data and a reduced rate of paravalvular leak, according to new research published in JACC: Cardiovascular Interventions and EuroIntervention.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup